Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
With
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Aim 1. Therapeutic HBV suppression will enhance antiviral immune effector responses and reduce immune inhibitory factors in participants with chronic hepatitis B. This study will also examine if antiviral therapy has a durable effect in host immune phenotype and define the immunological effect of interferon-alpha (IFNα) therapy in chronic HBV participants.
Aim 2. Antiviral immune effector and regulatory responses before, during and/or after therapy can predict long term therapeutic response.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability to provide informed consent for participation in the ancillary study
You may not be if
Children under 18 years of age
Pregnant women
Participants with anemia (Hgb\<10 or Hct\<30)
Participants with active medical conditions such as congestive heart failure or chronic lung disease requiring oxygen, active coronary artery disease with unstable angina, sepsis and renal failure
Participants with significant medical conditions, autoimmune disease or immunosuppression
